Compare BLZE & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | DNA |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 762.0M | 835.7M |
| IPO Year | 2021 | 2020 |
| Metric | BLZE | DNA |
|---|---|---|
| Price | $8.01 | $12.83 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 7 | 3 |
| Target Price | ★ $21.50 | $8.00 |
| AVG Volume (30 Days) | ★ 2.9M | 2.4M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.56 | 46.49 |
| EPS | ★ N/A | N/A |
| Revenue | $145,835,000.00 | ★ $170,155,000.00 |
| Revenue This Year | $22.06 | N/A |
| Revenue Next Year | $24.74 | $13.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.27 | N/A |
| 52 Week Low | $3.26 | $5.37 |
| 52 Week High | $23.99 | $18.22 |
| Indicator | BLZE | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.90 | 56.28 |
| Support Level | $6.82 | $6.75 |
| Resistance Level | $8.42 | $13.97 |
| Average True Range (ATR) | 0.76 | 1.37 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 43.00 | 66.95 |
Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.